Table 2.
Treatment and wait times divided by result of second EUS-FNA in patients who underwent repeat EUS-FNA for diagnosis of suspected pancreatic malignancy at St. Paul's Hospital, Vancouver, British Columbia, between 2007 and 2014.
| Cytopathology on 2nd EUS-FNA | Patients (n = 45) | Surgery performed | Chemotherapy started | Wait time to surgery or chemotherapy (days) | Interval between 1st and 2nd EUS-FNA (range) |
|---|---|---|---|---|---|
| Indeterminate | 7 (15%) | 0 | 0 | — | 28 (24–175) |
| Negative | 16 (35%) | 1 | 1 | 94, 148 | 39 (18–127) |
| Atypical | 8 (18%) | 1 | 1 | 36, 231 | 20 (9–37) |
| Likely | 3 (7%) | 2 | 0 | 33, 200 | 76 (16–80) |
| Diagnostic | 7 (16%) | 0 | 2 | 48, 265 | 19 (7–56) |
| NET | 3 (7%) | 2 | 0 | 84, 389 | 51 (28–56) |
| Lymphoma | 1 (2%) | 0 | 0 | — | 13 |
Treatment decisions and associated wait times following second EUS-FNA in patients with suspected pancreatic cancer (NET: neuroendocrine tumor; EUS-FNA: endoscopic ultrasound fine-needle aspiration).